Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 7,988 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 7,988 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $12.25, for a total transaction of $97,853.00. Following the completion of the transaction, the chief financial officer owned 137,987 shares of the company’s stock, valued at $1,690,340.75. This trade represents a 5.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA traded up $0.96 during trading hours on Friday, reaching $12.58. The company’s stock had a trading volume of 465,481 shares, compared to its average volume of 194,515. The firm has a market capitalization of $481.56 million, a price-to-earnings ratio of -3.64 and a beta of -0.12. The firm has a 50-day simple moving average of $11.05 and a 200-day simple moving average of $8.69. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $12.93.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $7.41 million. Equities analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Finally, Oppenheimer began coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds have recently bought and sold shares of TRDA. Millennium Management LLC raised its holdings in shares of Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the last quarter. Citadel Advisors LLC grew its position in Entrada Therapeutics by 234.5% in the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after purchasing an additional 235,384 shares during the period. Baker BROS. Advisors LP raised its stake in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after buying an additional 206,911 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in Entrada Therapeutics by 115.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock valued at $1,670,000 after buying an additional 154,143 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Entrada Therapeutics by 4,767.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock valued at $860,000 after buying an additional 145,167 shares during the period. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics News Roundup

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $20.00 price target on TRDA, which signals meaningful upside from current levels and likely supported buying interest. HC Wainwright note
• Positive Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate to a smaller loss (from ($1.20) to ($1.12)), a modest improvement that can be read as slightly better near‑term expectations for operating performance. HC Wainwright note
• Neutral Sentiment: Short‑interest data reported a jump claim but shows 0 shares short (short‑interest ratio 0.0 days); this appears to be a data anomaly. If accurate, near‑zero reported short interest reduces downward short‑pressure, but the feed’s inconsistency makes this point uncertain. Short interest report
• Negative Sentiment: HC Wainwright cut several near‑term EPS forecasts (Q2–Q4 2026 and FY2026 lowered; FY2026 moved to ($4.49) from ($4.21)) and trimmed multiple 2026/2027 quarterly EPS views, signaling larger expected losses in the near term. Deteriorating near‑term profitability expectations could pressure the stock if operational or cash‑burn concerns persist. HC Wainwright note

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.